Overexpression of estrogen receptor beta and its prognostic significance among malignant pleural mesothelioma patients

被引:0
|
作者
Helali, Mariam [1 ,3 ]
Abdelmotal, Ahmed [1 ]
Gobran, Nagy [1 ]
El Ghazaly, Hesham [1 ]
El Mahdy, Manal [2 ]
Karim, Khaled [1 ]
机构
[1] Ain Shams Univ, Fac Med, Clin Oncol Dept, Cairo, Egypt
[2] Ain Shams Univ, Fac Med, Pathol Dept, Cairo, Egypt
[3] 38 Abbassia,Next Al Nour Mosque, Cairo, Egypt
来源
EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS | 2024年 / 73卷 / 01期
关键词
mesothelioma; ER beta; prognostic; biomarkers; HEALTH;
D O I
10.4103/ecdt.ecdt_25_23
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background The overexpression of estrogen receptor beta (ER beta) and its correlation with prognosis of malignant mesothelioma remains controversial and unexplored. This study aimed at studying ER beta expression in tumour tissue in patients with pleural mesothelioma and its association with clinical and pathological factors and survival analysis. Material and methods A prospective cohort study was conducted on patients who were diagnosed with malignant pleural mesothelioma (MPM) in Ain Shams university hospitals, the primary end point was to correlate ER beta overexpression that was analysed by immunohistochemistry (IHC) on paraffin tissue blocks with 1-year overall survival (OS) among MPM patients, the secondary endpoint was to correlate ER beta overexpression with 1-year progression free survival (PFS) and response to platinum-based chemotherapy among MPM patients. Results A total 42 MPM patients were included, High ER beta expression (modified Allred score 7-9) was reported in 9.5% of the patients (4 cases), moderate expression (modified Allred score 4-6) was reported in 28.6% of the patients(12 cases), weak and negative expression ( modified Allred score 0-3) was reported in 61% of the patients(26 cases), percent of ER beta positive cases was 69% of the total patients, there was no statistical difference as regard age (p value:0.8), sex(p value:0.4), stage (p value: 0.71), ECOG (p value :0.84) , histological subtype(p value:0.17) and response to platinum based treatment (p value:0.5) across the 3 groups of patients (high, moderate , weak and negative ER beta on tumour tissues) there was no statistically significant difference in OS and PFS for ER beta overexpression. Conclusion The overexpression of ER beta was not associated with improved OS or PFS in mesothelioma patients, despite high rate of ER beta positive cases in our analysis, larger sample size would be recommended for more solid conclusions
引用
收藏
页码:85 / 90
页数:6
相关论文
共 50 条
  • [41] Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma
    Marcq, Elly
    Siozopoulou, Vasiliki
    De Waele, Jorrit
    van Audenaerde, Jonas
    Zwaenepoel, Karen
    Santermans, Eva
    Hens, Niel
    Pauwels, Patrick
    van Meerbeeck, Jan P.
    Smits, Evelien L. J.
    ONCOIMMUNOLOGY, 2017, 6 (01):
  • [42] Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
    S. T. Lee
    M. Ghanem
    R. A. Herbertson
    S. U. Berlangieri
    A. J. Byrne
    K. Tabone
    P. Mitchell
    S. R. Knight
    M. Feigen
    A. M. Scott
    Molecular Imaging and Biology, 2009, 11 : 473 - 479
  • [43] Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients
    Fournel, Ludovic
    Charrier, Thomas
    Huriet, Maxime
    Iaffaldano, Amedeo
    Lupo, Audrey
    Damotte, Diane
    Arrondeau, Jennifer
    Alifano, Marco
    LUNG CANCER, 2022, 166 : 221 - 227
  • [44] Molecular Profiling Predicts Outcomes in Patients With Resected Malignant Pleural Mesothelioma
    Rolfo, C. D.
    Perez, D. De Miguel
    Mallapelle, U.
    Grier, W.
    Pepe, F.
    Troncone, G.
    Culligan, M.
    Scilla, K. A.
    Mehra, R.
    Russo, A.
    Mohindra, P.
    Sachdeva, A.
    Hirsch, F. R.
    Wolf, A.
    Friedberg, J.
    Pickering, E. M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S311 - S312
  • [45] Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma
    Fujimoto, Nobukazu
    Ohnuma, Kei
    Aoe, Keisuke
    Hosono, Osamu
    Yamada, Taketo
    Kishimoto, Takumi
    Morimoto, Chikao
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S200 - S200
  • [46] Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers
    Creaney, Jenette
    Dick, Ian M.
    Musk, A. W.
    Olsen, Nola J.
    Robinson, Bruce W. S.
    BIOMARKERS, 2016, 21 (06) : 551 - 561
  • [47] Fibulin-3: A Potential Prognostic Biomarker in Malignant Pleural Mesothelioma?
    Kirschner, Michaela B.
    Pulford, Emily
    Hoda, Mir A.
    Rozsas, Anita
    Griggs, Kim
    Edelman, J. James B.
    Kao, Steven
    Hyland, Rebecca
    Dong, Yawen
    Laszlo, Viktoria
    Klikovits, Thomas
    Jakopovic, Marko
    Vallely, Michael
    Grusch, Michael
    Hegedus, Balazs
    Dome, Balazs
    Klepetko, Walter
    Van Zandwijk, Nico
    Klebe, Sonja
    Reid, Glen
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S747 - S747
  • [48] Poor Nutritional Status Is a Poor Prognostic Factor in Malignant Pleural Mesothelioma
    Hashimoto, M.
    Friess, M.
    Lauk, O.
    Weder, W.
    Opitz, I.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S747 - S747
  • [49] Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma
    Chiharu Tabata
    Eisuke Shibata
    Rie Tabata
    Shingo Kanemura
    Koji Mikami
    Yoshitaka Nogi
    Eriko Masachika
    Tomoyuki Nishizaki
    Takashi Nakano
    BMC Cancer, 13
  • [50] Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
    Lee, S. T.
    Ghanem, M.
    Herbertson, R. A.
    Berlangieri, S. U.
    Byrne, A. J.
    Tabone, K.
    Mitchell, P.
    Knight, S. R.
    Feigen, M.
    Scott, A. M.
    MOLECULAR IMAGING AND BIOLOGY, 2009, 11 (06) : 473 - 479